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Introduction
Autophagy is an intracellular process in which cell digests its own
constituents via the lysosomal degradative pathway [1].
Autophagy is a major pathway for degrading excess or damaged
organelles and proteins [2–4]. It has been shown that autophagy
is induced under various conditions like starvation [5], oxidative
stress [4, 6] and developmental cues [7]. While proliferating cells
can remove the ineffective mitochondria and lysosomes by cell
division, cardiac myocytes cannot do so because they are terminally
differentiated, and they maintain homeostasis only by activation of
degrading pathways such as macroautophagy, microautophagy
and chaperone-mediated autophagy [8]. Autophagy has been seen
in myocardial aging [2] and in several cardiac diseases including
heart failure [9], hypertrophy [10] and ischaemic cardiomyopathy
[11]. Inefficient or lack of autophagy causes the development of
age-related disorders and poor performance of the myocardium
[12]. Recently, autophagy is shown as an adaptive response in
failing hearts for protecting the myocardium from haemodynamic
stress [13] and shown to render cell survival in the myocardium
against ischaemia reperfusion (I/R) injury [14]. In another study,
it is shown that cardiac ischaemia-induced autophagy is protec-
tive, but reperfusion-induced autophagy is detrimental causing
cell death [15]. Nevertheless, the role of autophagy in the
myocardium, i.e. whether it mediate cell survival or cell death is
controversial [5, 12–16], and also the regulation and the underlying
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Autophagy is an intracellular process in which a cell digests its own constituents via lysosomal degradative pathway. Though autophagy
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ment attenuated hypoxic adaptation-induced LC3-II and BAG-1, and abolished improvement in cardiac cell survival and reduction of cell
death. These results clearly indicate that myocardial protection elicited by adaptation is mediated at least in part via up-regulation of
autophagy in association with BAG-1 protein.
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signalling mechanisms of autophagy are still poorly understood.
Cardiac adaptation to ischaemic stress achieved via repeated brief
periods of I/R is a well-known strategy for the protection of the
myocardium against subsequent I/R injury [17]. Myocardial adap-
tation is known to induce redox signalling, which converts death
signal into survival signal [17]. In the present study, in order to
evaluate the role of autophagy in the myocardium, we evaluated
the function of autophagy in cardiac ischaemic adaptation against
I/R injury. Although I/R injury is shown to induce autophagy in the
myocardium [14, 15], the role of autophagy during cardiac I/R
remains controversial with respect to the crucial question whether
autophagy contributes to cardiac cell survival or cell death. In
order to address this question, we evaluated the function of
autophagy during myocardial adaptation, which is a state-of-the-
art technique to protect the myocardium against the subsequent
I/R injury [17]. Cardiac adaptation to ischaemic stress induces the
production of reactive oxygen species, which in turn potentiates
the redox signalling and activates redox sensitive transcription
factors and survival proteins [17].
Several stress conditions like heat shock, oxidative stress, etc.
cause damage to a number of proteins, which are recognized by
molecular chaperones, leading to the activation of either cellular re-
folding processes or the degradation machinery directed to the
destruction of damaged proteins [18, 19]. However, molecular
mechanisms underlying the cooperation between the molecular
chaperones and the degradation machinery remain largely
unknown. Bcl-2-associated athanogene (BAG-1) is a multifunctional
protein, acts as a co-chaperone, and exerts many of its actions via
binding with chaperone molecules heat shock protein 70 (Hsp70)
and heat shock cognate protein (Hsc70) [20, 21]. BAG-1 is known
to suppress apoptosis induced by various stimuli including serum
withdrawal, heat shock and radiation – where BAG-1 binds with Bcl-
2 and prevent the release of pro-apoptotic factors [22]. BAG-1 pro-
tects cardiac myocytes from simulated I/R injury [23]. In addition,
BAG-1 directly binds with the components of ubiquitinylation
machinery and helps proteasome-mediated degradation [24].
Recently, it has been shown that autophagy is being regulated by
Bcl-2 binding molecules [25], and in another study, BAG-1 has been
identified in the molecular chaperone complex at the lysosomal
membrane required for protein degradation [26]. Very recently, it
has been demonstrated that the autophagosomal membrane con-
tains significantly higher amount of Hsc70 proteins [27]. Based on
the above reports, in the present study, we sought to evaluate the
possible role of BAG-1 in the regulation of autophagy.
When autophagy is induced, phagophore [otherwise known
as isolation membrane] formation occurs via Beclin-1-depend-
ent mechanism [28, 29]. In a separate pathway, processing of
microtubule-associated protein light chain 3 (LC3) is initiated,
where LC3 is cleaved to form LC3-I, which is further processed
to form LC3-II [28, 29]. LC3-II is being incorporated into the
isolation membrane, which surrounds the autophagic sub-
strates like damaged proteins or organelles [28, 29]. The final
structure is known as autophagosome. Autophagosomes then
fuse with lysosomes for the digestion of autophagic substrates
[28, 29]. The autophagosomal membrane bound LC3-II is being
used as a specific marker to study autophagy [30, 31]. In mam-
malian cells, autophagy is shown to be activated by class III
phosphatidylinositol-3 (PI-3) kinase complex containing 
Vps34 and Beclin-1 [28, 29]; Wortmannin, an inhibitor of class
III PI-3 kinase has been used in several studies to suppress
autophagy [32, 33]. In the present study, we injected rats with
Wortmannin (15 g/kg, intraperitoneally) 30 min. before isola-
tion of heart in order to suppress the autophagy elicited by
ischaemic adaptation.
Materials and methods
Animals
All animals used in this study received humane care in compliance with the
Animal Welfare Act and other federal statutes and regulations relating to
animals and experiments involving animals and adhered to principles
stated in the Guide for the Care and Use of Laboratory Animals, NRC
Publication, 1996 edition. Sprague Dawley male rats weighing between
250–300 gm were fed ad libitum regular rat chow with free access to water
until the start of the experimental procedure. The rats were randomly
assigned to one of the following three groups: normal control [N], I/R and
ischaemic adaptation.
Isolated working heart preparation
Rats were anaesthetized with sodium pentobarbital (80 mg/kg, intraperi-
toneally), (Abbott Laboratories, North Chicago, IL, USA) and with the anti-
coagulant heparin sodium (500 IU/kg, i.v.) (Elkins-Sinn, Inc., Cherry Hill,
NJ, USA). After ensuring sufficient depth of anaesthesia, thoracotomy was
performed; hearts were isolated and perfused in the retrograde
Langendorff mode at 37C at a constant perfusion pressure of 100 cm of
water (10 kPa) for a 5-min. washout period. The perfusion buffer used in
this study consisted of a modified Krebs-Henseleit bicarbonate buffer
(KHB) (in mM: sodium chloride 118, potassium chloride 4.7, calcium chlo-
ride 1.7, sodium bicarbonate 25, potassium biphosphate 0.36, magnesium
sulphate 1.2 and glucose 10).
At the end of 10 min., after the attainment of steady state cardiac func-
tion, baseline functional parameters were recorded. Ischaemic adaptation
group hearts were subjected to four cyclic episodes of 5 min. ischaemia
each followed by 10 min. of reperfusion. I/R and ischaemic adaptation
group hearts were then subjected to 30 min. of global ischaemia followed
by 2 hrs of reperfusion. The first 10 min. of reperfusion was in the retro-
grade mode to allow for post-ischaemic stabilization and there after in the
antegrade working mode to allow for assessment of functional parameters,
which were recorded at 30-, 60- and 120-min. reperfusion. Control hearts
were collected after 2 hrs and 45 min. retrograde perfusion in Langendorff
apparatus. Wortmannin (15 g/kg) was injected into rats via intraperi-
toneal route 30 min. before isolation of heart.
Isolated non-working heart and drug treatment
After anaesthetizing and heparinizing rats as mentioned under working
heart preparation, hearts were isolated and perfused in Langendorff mode
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for 15 min. I/R group hearts were subjected to 30 min. of ischaemia fol-
lowed by 2 hrs of reperfusion. Ischaemic adaptation group hearts were
subjected to four cyclic episodes of 5 min. of ischaemia and 10 min. of
reperfusion, followed by 30 min. of ischaemia and 2 hrs of reperfusion.
Normal control hearts were collected after 10 min. of retrograde perfusion
in Langendorff apparatus. Wortmannin (15 g/kg) was injected into rats
via intraperitoneal route 30 min. before isolation of heart.
Cardiac function assessment
Aortic pressure was measured using a Gould P23XL pressure transducer
(Gould Instrument Systems Inc., Valley View, OH, USA) connected to a
side arm of the aortic cannula. The signal was amplified using a Gould
6600 series signal conditioner and monitored on a CORDAT II real-time
data acquisition and analysis system (Triton Technologies, San Diego, CA,
USA). Heart rate, left ventricular developed pressure (defined as the differ-
ence of the maximum systolic and diastolic aortic pressures), and dp/dt
were all derived or calculated from the continuously obtained pressure sig-
nal. Aortic flow was measured using a calibrated flow meter (Gilmont
Instrument Inc., Barrington, IL, USA) and coronary flow was measured by
timed collection of the coronary effluent dripping from the heart.
Infarct size estimation
At the end of reperfusion, the left ventricle was cut into transverse slices.
The slices were incubated in 1% triphenyl tetrazolium solution in phosphate
buffer (Na2-HPO4- 88 mM, NaH2-PO4- 1.8 mM) for 20 min. at 37C. This pro-
cedure distinguishes necrotic tissue from viable myocardium. The slices
were stored for 48 hrs in 10% buffered formalin. The heart slices were pho-
tographed and the weights of the slices were monitored. Digital images of
the slices were magnified, and the area of necrosis in each slice was quan-
tified by computerized planimetry. The risk and infarct volumes in cubic
centimetre of each slice were then calculated on the basis of slice weight to
remove the introduction of any errors due to non-uniformity of heart slice
thickness. The risk volumes and infarct volumes of each slice were summed
to obtain the risk and infarct volumes for the whole heart. Infarct size was
taken to be the percent infarct volume of risk volume for any one heart.
Transmission electron microscopy (TEM)
Small tissue samples about 1 mm3 were fixed by immersion in 4% glu-
taraldehyde, post-fixed for 1 hr in 1% OsO4 in 0.1 M cacodylate buffer,
dehydrated and embedded in Epon 812 at 60C for 48 hrs, as previously
described [34, 35]. Routine 60-nm ultra-thin sections were cut and mounted
on coated grids, stained with 1% uranyl acetate and Reynold’s lead citrate.
The TEM examination was performed with Philips CM 12 at 60 kV and dig-
ital images were recorded with Morada CCD, iTEM (Olympus Soft Imaging
Solutions, Munster, Germany).
In vivo BAG-1 siRNA treatment
Survival surgeries in animals were performed as mentioned in our previ-
ous studies [36]. Briefly, the rats were anaesthetized by intraperitoneal
injection of ketamine [100 mg/kg] and xylazine (2 mg/kg). Additional doses
of ketamine and xylazine were given during the protocol as needed to
maintain anaesthesia. Intraperitoneal dosage of buprenorphine hydrochlo-
ride (0.1 mg/kg) was given for analgesia. Before starting the surgery, rats
were also given subcutaneous gentamycin (1 mg/kg). Tracheal intubation
was performed with a 14-gauge catheter, and animals were artificially ven-
tilated with mixture of air and oxygen using a respirator (Harvard-rodent
ventilator model 683, South Natick, MA, USA). Respiratory rates were main-
tained at 70/min. and tidal volume 10 ml/kg. For direct gene delivery, a small
oblique thoracotomy is performed lateral to the midsternal line in the fourth
intercostal space to expose the heart. A single injection of either control or
BAG-1 siRNA (100 l of 10 M) was delivered with a 30-gauge needle into
the anterior left ventricular wall 1 mm into the myocardium at a very shallow
angle (10–20) in a cranial direction approximately 3 mm below the auricle
of the left atrium between the left anterior descending artery and the left atrial
branch. The chest was closed in layers with 4–0 nylon suture and animal was
allowed to recover. After the operation, intraperitoneal injection of buprenor-
phine hydrochloride (0.1 mg/kg) for analgesia and gentamycin (1 mg/kg)
was added every 12 hrs for 3 days. Forty-eight hours after survival surgery,
animals’ hearts were isolated and subjected to working heart studies.
Cytosolic extract preparation
About 100 mg of left ventricular tissue was homogenized in 1 ml of buffer
containing 25 mM Tris, 25 mM NaCl, 1 mM sodium orthovanadate, 10 mM
sodium fluoride, 10 mM sodium pyrophosphate, 10 nM okadaic acid, 0.5 mM
ethylenediaminetetraacetic acid (EDTA), 1 mM PMSF and protease inhibitors
cocktail (leupeptin, aprotinin and pepstatin). Homogenates were centrifuged
at 3000 rpm for 10 min. at 4C, and the supernatant was again centrifuged at
10,000 rpm for 20 min. at 4C. The resultant supernatant was saved as
cytosolic extract. Total protein concentration in the cytosolic extract was
determined using BCA Protein Assay Kit (Pierce, Rockford, IL, USA).
Immunoprecipitation
Cytosolic extract containing 500 g of total protein was immunoprecipi-
tated with BAG-1 (Santa Cruz Biotechnology, Santa Cruz, CA) and protein A
Sepharose beads (Zymed, San Francisco, CA, USA) for overnight at 4C.
Pellets were collected by centrifuging at 10,000  g for 30 sec. at 4C, and
washed three times with ice-cold wash buffer (50 mM Tris-HCl, pH 7.4, 
150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, and 
2 mM EDTA). Pellets were resuspended in 1 Laemmli sample buffer, and
boiled at 95–100C for 10 min. Western immunoblotting was done as
described below.
Western blot analysis
Cytosolic proteins were separated in SDS-PAGE and transferred to nitro-
cellulose filters. Filters were blocked in 5% non-fat dry milk, and probed
with a primary antibody for overnight. Primary antibodies such as 
BAG-1, LC3, Beclin-1, Hsp70, Hsc70 and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) were obtained from Santa Cruz Biotechnology,
and used at 1:500 dilutions, except in case of GAPDH (1:1000). Caspase-
3 antibody obtained from Cell Signaling Technology, Inc. (Danvers, MA,
USA) and used in 1:1000 dilution. Caspase-3 antibody detects endoge-
nous levels of full length caspase-3 (35 kD) and the cleaved fragment 
(17 kD) of caspase-3 resulting from apoptosis. Protein bands were 
© 2009 The Authors
Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
376
identified with horseradish peroxidase-conjugated secondary antibody
(1:2000 dilution) and Western blotting Luminol reagent (Santa Cruz
Biotechnology). The resulting blots were digitized, subjected to densito-
metric scanning using a standard NIH image program and normalized
against loading control.
Immunofluorescence techniques and image analysis
Heart tissue samples collected at the end of experiments were fixed in 2%
buffered paraformaldehyde (pH 7.4), embedded and frozen in O.C.T. com-
pound, and subjected to cryosectioning. The 5-m cryosections of the
obtained specimens were processed for immunofluorescence analysis.
The primary antibody against (i ) Bag-1 [rabbit polyclonal IgG from Santa
Cruz Biotechnology, Inc., www.scbt.com], (ii ) LC3 (goat polyclonal IgG
from Santa Cruz Biotechnology, Inc.), were used in 1:250 dilution. This
was followed by incubation with secondary fluorochrome-conjugated anti-
body and counterstaining with Heochest 33342 (Molecular Probes, Inc.,
Eugene OR, USA) diluted 1:1000. The secondary antibodies used were 
(i ) ALEXA 488 conjugated goat anti-rabbit IgG (Molecular Probes, Inc.),
(ii ) ALEXA 594 conjugated chicken anti-IgG (Rockland, Inc., Gilbertsville,
PA, USA); negative controls for non-specific binding included normal goat
serum without primary antibody or with secondary antibody alone. The
labelled specimens were rinsed, mounted in Gelvatol (Monsanto Corp., St.
Louis, MO, USA), and cover slipped for fluorescence microscopy.
Immunofluorescence and Nomarski Interference Contrast images were
obtained using Olympus AX 80 microscope (Center Valley, PA, USA), fitted
with a charge-coupled device (CCD) Hamamatsu Orca camera at magnifi-
cation 40. Each of the three colour images was scanned separately, by
using Olympus 4-6-Diamidino-2-phenylindole (DAPI), fluorescein isothio-
cyanate (FITC), and Rhodamine filter cubes. The background fluorescence
was determined for BAG-1 and LC3-II from images specimens labelled
with the secondary antibodies only. Higher magnification confocal
immunofluorescence microscopic images for the group IA was conducted
with a 100 1.4 numerical aperture (zoom 2) objective lens on Nikon
Eclipse E800/Bio-Rad Radiance 2100 confocal microscope (Hercules, CA,
USA). The projections presented are individual XY confocal images from
the respective stacks taken with 0.5-m Z-steps. Inset ‘ZX’ presented in
the panel H is ZX optical re-slicing of the region of interest (ROI) indicated
in the panel with arrows (Note blue channel has been excluded). Spatial co-
localization of BAG-1 (green channel) and LC3-II (red channel) in the panel
H (ZX) appears in yellow colour as a result of interference between green
and red colours. Pearson’s correlation coefficient for signals of green and
red channels in the indicated area is r  0.29. Processing and analysis of
digital images, including colocalization of immunostained BAG-1 and LC3
was conducted with SimplePCI High Performance Imaging software
(Compix, Inc., Hamamatsu Co., www.cimaging.net) and Image J software.
The results are representative images of three separate experiments.
Cell culture
Rat myocardium derived H9c2 cardiac myoblast cell line was purchased
from the American Type Culture Collection (ATCC; Manasses, VA, USA).
Cells were grown on Dulbecco’s modified Eagle’s medium (DMEM,
Invitrogen, Grand Island, NY, USA) containing 4 mM l-glutamine, 4.5 g/l
glucose, and 10% foetal bovine serum (Invitrogen) and incubated at 37C
in a humidified chamber with 5% CO2. To prevent the loss of differentiation
potential, cells were not allowed to become confluent.
In vitro siRNA transfection
To each well of six-well tissue culture plate, 2  105 H9c2 cells were
seeded with 2 ml DMEM growth medium containing antibiotics. Plates
were incubated for 18–24 hrs till it reaches 70–80% confluency. BAG-1
and control siRNAs were obtained from Santa Cruz Biotechnology (Santa
Cruz, CA, USA), and used at the final concentration of 25 nM. siRNA trans-
fection was done using TransPass R2 transfection reagent (New England
BioLabs) as mentioned in the kit. Cells are grown in complete growth
medium containing 10% serum for an additional period of 48 hrs. Follow-
up experiments are performed at the end of 48 hrs incubation period.
Hypoxia-reoxygenation in cell culture
Normal or siRNA transfected H9c2 culture plates were subjected to either
30 min. of hypoxia or 30 min. of hypoxia followed by 1 hr of reoxygenation
(H/R) or hypoxic adaptation, where the cells were subjected to three cyclic
episodes of 5 min. hypoxia and 5 min. reoxygenation, followed by H/R
[37]. Hypoxia was given by placing the cultured plates into an air-tight
hypoxic chamber placed in a humidified 37C CO2 incubator, and passing
the mixture of 95% nitrogen and 5% CO2. Reoxygenation was given by
placing back the cultured plates in a humidified 37C CO2 incubator satu-
rated with air.
Cell survival assay
At the end of experimentation, cells were washed with phosphate buffered
saline (PBS). Viability of cells was studied using MTT Cell Proliferation
Assay kit (Cayman Chemical Company, Ann Arbor, MI, USA) as mentioned.
Cell death assay
Cell death analysis was performed with the spent culture medium as sub-
strate with lactate dehydrogenase (LDH) Cytotoxicity Assay kit (Cayman
Chemical Company) as mentioned.
Immunofluorescence staining in H9c2 cells
Cells were washed with PBS and fixed using 4% paraformaldehyde solu-
tion for 20 min. After washing with PBS, the slides were blocked with
Powerblock (BioGenex, San Ramon, CA, USA) for 10 min. Slides were
again washed with PBS and incubated with either single or multiple pri-
mary antibodies (rabbit polyclonal BAG-1; goat polyclonal LC3) used at
1:20 dilution in PBS containing 1% BSA for 2 hrs at room temperature.
Slides were washed and incubated with fluorescein-conjugated secondary
antibodies (anti-rabbit Alexa Fluor 488; anti-goat Alexa Fluor 594) used at
1:500 dilution in dark for 45 min. at room temperature. Nuclear staining
was done with To-Pro 1 iodide [Molecular Probes, Inc.] at 1:500 dilution
for 45 min. in the dark. The slides were washed and covered with mount-
ing medium, and examined under a fluorescence microscope. Confocal
microscopic images were obtained using Zeiss LSM 510 (Thornwood, NY,
USA) confocal laser scanning microscope with 40 1.3 oil immersion
objective by simultaneous recording in the 488, 530 and/or 560  channels
as appropriate.
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Cell lysate preparation
At the end of experimentation, cells were washed with PBS, and lysed in
radio immuno precipitation assay (RIPA) buffer (Boston Bioproducts,
Boston, MA, USA) supplemented with protease inhibitor cocktail (Sigma)
and a phosphatase inhibitor (100 mM sodium orthovanadate) on ice for 
1 hr. Lysate was centrifuged at 10,000 rpm for 10 min. at 4C, and the
supernatant was mixed with sample buffer and heated at 95C for 5 min.,
and used for Western immunoblotting.
Statistical analysis
The values for myocardial functional parameters, total and infarct volumes
and infarct sizes were all expressed as the mean 	 standard error of mean
(S.E.M.). Analysis of variance test followed by Bonferoni’s correction was
first carried out to test for any differences between the mean values of all
groups. If differences between established, the values of the treated groups
were compared with those of the control group by a modified t-test. The
results were considered significant if P 
 0.05.
Results
Myocardial adaptation to ischaemic stress
enhances autophagy
In this study, when isolated rat hearts were subjected to 30 min.
of global ischaemia followed by 2 hrs reperfusion, autophagic
marker proteins such as LC3-II and Beclin-1 were slightly induced
in the myocardium relative to control rat hearts (Fig. 1A).
Moreover, cardiac adaptation by subjecting the hearts to four
cyclic episodes of 5 min. of global ischaemia and 10 min. of reper-
fusion preceding I/R injury further induced both LC3-II and Beclin-
1 (Fig. 1A). Quantitative analysis of Western immunoblotting of
LC3 (Fig. 1B), Beclin-1 (Fig. 1C) and BAG-1 (Fig. 1D) show that
LC3, Beclin-1 and BAG-1 were significantly up-regulated in the
hearts after ischaemic adaptation. Furthermore, autophagosome
formation in our experimental samples was confirmed by trans-
mission electron microscopy. TEM images show that autophago-
somes formed during I/R is selective containing mitochondria
(Fig. 1E). However, several autophagosomes containing partially
degraded cytoplasmic materials and mitochondria were found in
the myocardium adapted for ischaemic stress (Fig. 1E). These
results suggest that although autophagy is slightly induced during
cardiac I/R, it is significantly induced when a survival signal is
generated via ischaemic stress adaptation.
Ischaemic adaptation enhanced BAG-1 
in the myocardium
I/R injury slightly induced the expression of BAG-1 protein, but it
was significantly elevated after ischaemic adaptation preceding I/R
injury (Fig. 1A and D). These results show a positive correlation
between the induction of autophagy and BAG-1 protein.
Autophagosomal membrane protein LC3 binds
with BAG-1
Cytoplasmic protein extract was immunoprecipitated with BAG-1
specific antibody and the immunoprecipitate was analysed for
autophagosomal membrane protein LC3-II by Western
immunoblotting. We found that LC3-II protein was present in the
BAG-1 immunoprecipitate, where significantly higher amount of
LC3-II was bound in the BAG-1 immunoprecipitate obtained from
the hearts subjected to adaptation relative to I/R (Fig. 2). Further,
in order to confirm the binding of LC3 with BAG-1, we performed
co-immunofluorescence analysis with BAG-1 and LC3 specific
antibody using myocardial tissue sections. Figure 3 shows the
staining of BAG-1 in green channel (B and F), and the staining of
LC3 in red channel (C and G). The merged picture (D and H)
shows the co-localization LC3 and BAG-1 in yellow. Taken
together, our results indicate that BAG-1 binds with autophagoso-
mal membrane specific protein LC3 in the cytoplasmic region.
Inhibition of autophagy inhibits BAG-1 expression
Treatment with Wortmannin significantly attenuated adaptation-
induced improvement in cardiac functional parameters such as
left ventricular developed pressure and aortic flow (Fig. 4).
However, heart rate and coronary flow were not significantly
affected by Wortmannin treatment (Fig. 4). Also, Wortmannin
treatment partially abolished the adaptation-induced reduction of
infarct size (Fig. 5A and B). Western blot analyses show that 
treatment with Wortmannin attenuated cardiac adaptation-induced
LC3-II, Beclin-1 and BAG-1 (Fig. 5C–F).
In vivo treatment with BAG-1 siRNA attenuated
autophagy in the myocardium
We found that BAG-1 protein was simultaneously induced when
autophagy was induced. In order to further demonstrate the role
of BAG-1 in autophagy, we studied the effect of BAG-1 inhibition
in autophagy. We employed RNA interference technique to sup-
press the expression of BAG-1 protein through direct injection of
BAG-1 siRNA into the myocardium of rats. Forty-eight hours after
siRNA injection, the hearts were collected and subjected to
ischaemic adaptation followed by I/R. Cardiac function like aortic
flow, left ventricular developed pressure and the first derivative of
left ventricular developed pressure (dp/dt) were markedly reduced
by BAG-1 siRNA treatment when compared to control siRNA
treated hearts (Fig. 6A–C). Western immunoblot analysis shows
that BAG-1 siRNA injection suppressed BAG-1 protein expression
when compared to control siRNA treated hearts (Fig. 6D).
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Moreover, BAG-1 siRNA treatment attenuated adaptation-induced
up-regulation of autophagic marker protein LC3-II relative to con-
trol siRNA treated hearts (Fig. 6E). Cardiac cell death by apoptosis
was evaluated by examining the protein expression of cleaved or
activated caspase-3. Figure 6F shows that BAG-1 siRNA treatment
markedly up-regulated the expression of activated caspase-3
when compared to control siRNA treated hearts. Furthermore,
LDH activity, a marker for cell death, was significantly increased 
in the coronary effluent collected from BAG-1 siRNA treated
hearts during reperfusion period relative to control siRNA treated
hearts (Fig. 6G). These results clearly indicate that BAG-1 siRNA
treatment attenuated autophagy and at the same time up-regulated
cell damage via necrosis and apoptosis, which is evident from
increased LDH activity in the coronary effluent of BAG-1 siRNA
treated hearts.
Hypoxic adaptation in cardiac myoblast cells
induces autophagy and BAG-1
Our in vivo study results show that cardiac adaptation induced
autophagy in association with BAG-1 protein. These results were
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Fig. 1 Ischaemic adaptation induces autophagy. (A) – Cytoplasmic extract from left ventricular tissue was isolated, proteins were separated by SDS-
PAGE and analysed by Western immunoblotting using specific antibodies. (B–D) – Quantitative analysis of Western immunoblotting of LC3 (B), Beclin-
1 (C) and BAG-1 (D); the results are represented as fold change in comparison to control heart samples. Quantitation of LC3 is calculated by analysing
the expression ratio of LC3-II / LC3-I. The expression of Beclin-1 and BAG-1 is normalized with the expression of GAPDH. *P 
 0.05 versus control.
(E) – Transmission electron micrographs of left ventricular tissue sections showing autophagosomes, indicated by arrows in control (a) ischaemia and
reperfusion (b) and ischaemic adaptation followed by I/R (c). Autophagosomes contain mitochondria (m) and partially degraded material, which is 
indicated by * in (b) and (c). Scale bar represents 2 . Results are representative images of three to five separate samples. C – Control, I/R – ischaemia
and reperfusion, IA – Ischaemic adaptation followed by I/R.
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further tested in vitro using H9c2 cardiac myoblast cells. H9c2
cells were subjected to 30 min. of hypoxia followed by 60 min. of
reoxygenation (H/R). The hypoxic adaptation was induced by three
repeated cycles of 5 min. of hypoxia and 5 min. of reoxygenation
preceding H/R. H/R in cardiac myoblast cells induced the expres-
sion of LC3-II, and BAG-1 proteins (Fig. 7A–C). However, when
H9c2 cells were subjected to hypoxic adaptation preceding the
H/R, LC3-II and BAG-1 proteins were significantly enhanced as
shown by Western immunoblotting in Fig. 7A–C. In accordance
with the results shown in Fig. 3, our immunofluorescence analy-
ses of H9c2 cells showed that the expression of LC3 and BAG-1
was increased in cells subjected to hypoxic adaptation followed by
H/R. Representative immunofluorescence images (Fig. 7D and E)
showing the staining of BAG-1 and LC3, respectively, in cells sub-
jected hypoxic adaptation. Figure 7F shows the co-localization
BAG-1 and LC3 in H9c2 cells subjected to hypoxic adaptation. This
indicates that the results obtained in cardiac myoblast cells are in
consistent with the results obtained in rat myocardium.
BAG-1 siRNA treatment in cardiac myoblast cells
attenuated hypoxic adaptation-induced autophagy
When cardiac myoblast cells are treated with either control or
BAG-1 siRNA, the hypoxic adaptation-induced expression of BAG-1
protein was decreased in BAG-1 siRNA treated cells compared to
control siRNA treated cells (Fig. 8A and B). At the same time, the
hypoxic adaptation-induced expression of LC3-II was also attenu-
ated in BAG-1 siRNA treated cells compared to control siRNA
treated cells (Fig. 8A and C).
Further, cell death by apoptosis was evaluated by examining
the protein expression of activated caspase-3. Figure 8A and 
D shows that in vitro BAG-1 siRNA treatment preceding HA in
H9c2 cardiac cells significantly enhanced the expression of acti-
vated caspase-3 when compared to cells treated with control
siRNA. The release of LDH into the spent culture medium show
that H/R in cardiac myoblast cells significantly induced LDH
release (Fig. 8E). H/R-induced LDH release is significantly atten-
uated by hypoxic adaptation in myoblast cells (Fig. 8E). Hypoxic
adaptation-induced attenuation of LDH release was blocked
when the cells are treated with BAG-1 siRNA compared to con-
trol siRNA (Fig. 8E). Moreover, cell survival assay using 3(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) in H9c2
cells indicated that the hypoxic adaptation-induced improvement
in cell survival probability was attenuated by treating cells with
BAG-1 siRNA relative to control siRNA (Fig. 8F). Altogether,
these results clearly indicate that autophagic marker LC3-II and
cellular survivability in cardiac myoblast cells were decreased
when the expression of BAG-1 was diminished via treatment with
BAG-1 siRNA.
Altogether, our results show that ischaemic adaptation of the
myocardium enhances autophagy and BAG-1, and the
autophagosomal membrane specific protein microtubule-
associated protein LC3 interacts with BAG-1. Moreover, the
essential role of BAG-1 in the induction of autophagy has been
proved by BAG-1 siRNA treatment in vivo and in vitro. These
results indicate that ischaemic adaptation-induced cardiac pro-
tection is mediated at least in part via up-regulation of
autophagy, and BAG-1 appears to play an important role in the
induction of autophagy.
Discussion
A lot of work has been done on the mechanism of ischaemic adap-
tation-induced cardioprotection [17], and recently, the protective
effect of autophagy has been demonstrated under anoxia-reoxy-
genation in isolated cardiomyocytes [37].
In this study, our results reveal the following novel findings: 
(i ) ischaemic adaptation of the myocardium enhances autophagy
and BAG-1, (ii ) autophagosomal membrane specific protein LC3-II
interacts with BAG-1, (iii ) inhibition of autophagy by treating rats
with Wortmannin attenuates BAG-1 protein expression and (iv)
suppression of BAG-1 protein expression by in vivo BAG-1 siRNA
treatment into the myocardium attenuated adaptation-induced
autophagy. Further, treatment with BAG-1 siRNA in H9c2 cardiac
myoblast cells attenuated hypoxic adaptation-induced LC3-II and
cell survival.
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Fig. 2 LC3-II interacts with BAG-1. Cytoplasmic extracts of the left ven-
tricular tissue is immunoprecipitated with BAG-1 specific antibodies.
BAG-1 immunoprecipitates were separated by SDS-PAGE, and Western
immunoblotting was performed with specific antibodies. Results are rep-
resentative images of three separate experiments. C – Control, I/R –
Ischaemia and reperfusion, IA – Ischaemic adaptation followed by I/R, 
T – cytosolic extract from IA sample.
380
Is autophagy in the myocardium protective 
or detrimental?
Autophagy acts as cellular defence mechanism against bacterial
toxins [33]. Autophagy is shown to be induced in several cardiac
diseases like heart failure [9], cardiac hypertrophy [10] and
ischaemic cardiomyopathy [11]. Hamacher-Brady et al. have
demonstrated that enhancing autophagy protects against I/R
injury in cardiac myocytes [14]. Overexpression of Bnip3, a 
pro-apoptotic molecule present in the mitochondrial membrane,
triggered up-regulation of autophagy and protected cardiac
myocytes from I/R injury-related apoptosis [38]. A recent study
demonstrates that autophagy elicited by hypoxia or ischaemia via
AMP activated protein kinase-dependent mechanism may provide
protective role against cardiac injury; but autophagy elicited by
ischaemia followed by reperfusion occurring via Beclin-1-depend-
ent mechanism may play a detrimental role in the myocardium
[15]. In another study, reduction of autophagy by RNA interfer-
ence of Beclin-1, a key molecule involved in mediating autophagy,
© 2009 The Authors
Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 3 Colocalization of BAG-1 and LC3. Immunofluorescence imaging of the expression of BAG-1 (B) and LC3 (C) in tissue sections obtained from hearts
subjected to ischaemia and reperfusion (I/R), ischaemic adaptation followed by ischaemia and reperfusion (IA), and from control (Con) rats. (A), (E) – coun-
terstaining of nuclei with Hoechst 33342 (blue channel); (B), (F) – immunofluorescence staining of BAG-1 (Alexa 488, green channel); (C), (G) – immuno-
fluorescence staining of LC3-II (Alexa 594, red channel); (D), (H) – overlay of blue, green and red channels; (K) – Nomarski interference contrast images
of the specimens; L – overlay of images presented in the (D) and (K). Confocal images showing the colocalization of BAG-1 and LC3 in IA heart samples
(E–H). Bars in the images (A), (B), (C), (D), (K) and (L) are representing 100 m. Bars in the images (E)–(H) are representing 10 m.
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enhances cardiac cell survival [39]. In order to address the contro-
versial role of autophagy in the myocardium, in the present study
we examined the function of autophagy during cardiac adaptation
to ischaemic stress. Our study, in accordance with previous results
[14], shows that autophagy was slightly up-regulated by I/R injury
(Fig. 1). In addition, our results indicate that cardiac adaptation to
ischaemic stress further enhanced autophagy as demonstrated by
the up-regulation of autophagosomal membrane specific protein
LC3-II, and Beclin-1 (Fig. 1A–C), and by the presence of
autophagosomes (Fig. 1E). Further, hypoxic adaptation in cardiac
myoblast cells induced the expression of LC3-II as shown by
Western immunoblotting and immunoflorescence analyses (Fig. 7).
These results suggest that cardiac adaptation, a state-of-the-art
technique to protect the myocardium against I/R injury, may trig-
ger cell survival at least in part via the up-regulation of autophagy.
BAG-1, a co-chaperone, binds with 
autophagosomal membrane protein LC3
BAG-1 is a multifunctional pro-survival molecule that binds with
Bcl-2 and protects cells from apoptosis [21, 22]. BAG-1 functions
as a nucleotide exchange factor of mammalian cytosolic Hsc70,
thereby triggering substrate unloading from the chaperone [40].
BAG-1 is shown to promote the association of Hsp70/Hsc70 with
proteasome in vitro [41]. The ubiquitin domain protein BAG-1 and
the carboxyl terminus of the Hsc70-interacting protein (CHIP)
ubiquitin ligase can cooperate to shift the activity of the
Hsc70/Hsp70 chaperone system from protein folding to degrada-
tion [42]. BAG-1 has been shown to protect cardiac myocytes from
simulated I/R injury-induced apoptosis in association with Hsp70
and Hsc70 chaperone molecules [23]. This BAG-1-mediated car-
dioprotection was shown to be critical upon cytoplasmic localiza-
tion but independent of its association with proteasome as shown
that BAG-1 induced cardioprotection was not affected by a BAG-1
deletion mutant lacking N-terminal ubiquitin-like domain, which
mediates interaction with proteasome [23]. These results suggest
that BAG-1 may provide a novel cardioprotective role, which may
be independent of its association with proteasome [23].
Recently, it has been shown that autophagy is being regulated
by Bcl-2 binding Beclin-1 [25]. BAG-1 is shown to present in the
molecular chaperone complex at the lysosomal membrane along
with Hsp70 and Hsc70 [26]. In another study, it has been demon-
strated that autophagosomal membrane contains significantly
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Fig. 4 Myocardial function after treatment with Wortmannin, an inhibitor of autophagy. Rats were injected with Wortmannin (15 g/kg, intraperitoneally)
30 min. before isolation of heart. Hearts were perfused in Langendorff working heart apparatus in working mode. Myocardial functional parameters like
heart rate (A), coronary flow (B), aortic flow (C) and left ventricular developed pressure (D) were recorded. Results are representative images of six ani-
mals 	 S.E.M. *P 
 0.05 versus IA  Wort.
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higher amount of Hsc70 proteins [27]. Since BAG-1 can bind with
both Bcl-2 and Hsc70 molecules, we studied the possible role of
BAG-1 protein in the regulation of autophagy. In the present study,
we found that I/R injury slightly up-regulated BAG-1 protein
expression, but upon ischaemic adaptation the BAG-1 protein
expression was further enhanced in the myocardium. Moreover,
hypoxic adaptation against hypoxia and reoxygenation in cardiac
myoblast cells also induced BAG-1 protein. Our in vivo and in vitro
studies show that BAG-1 protein expression is positively corre-
lated with the expression of autophagosomal marker proteins.
Further, our immunoprecipitation experiment with the cytosolic
extract of the myocardium show that BAG-1 binds with LC3-II, and
the binding was enhanced during ischaemic adaptation (Fig. 2). In
addition, our co-immunofluorescence analysis shows that LC3 is
co-localized with BAG-1 in the myocardium (Fig. 3). However, it is
not known that whether BAG-1 directly interacts LC3-II or indi-
rectly through other molecules. BAG-1 is shown to exert many of
its functions via interaction of heat shock protein Hsc70 [22].
Recently, it has been shown that Hsc70 is present in significantly
higher level in autophagosomal membrane [27]. LC3-II is a 
specific molecule found in the autophagosomal membrane [29].
In our study, we found that Hsc70 co-immunoprecipitate with
BAG-1. Based on the above evidence, we speculate that BAG-1
may interact with LC3 via Hsc70.
Inhibition of autophagy abolished the 
cardioprotective abilities of ischaemic 
adaptation and attenuated BAG-1 protein
In mammalian cells, autophagy is shown to be activated by class
III PI3 kinase complex containing Vps34 and Beclin-1 [28, 29],
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Fig. 5 Inhibition of autophagy inhibits IA-induced reduction of myocardial infarct size and BAG-1. Rats were injected with Wortmannin (15 g/kg,
intraperitoneally) 30 min. before isolation of heart. Hearts were perfused in Langendorff mode, and at the end of reperfusion, hearts were collected and
cut into several sections. Heart sections were stained with 1% triphenyltetrazolium chloride solution. Infarct size analysis (A) was carried out using Scion
Image software. (B) – Representative cardiac tissue sections showing infarct zone (white area). *P
 0.05 versus I/R, and Wort  IA. (C) – Hearts were
isolated from Wortmannin treated rats, and perfused in Langendorff mode as mentioned in methods. Cytoplasmic extract from left ventricular tissue
was isolated, and the proteins were separated by SDS-PAGE and analysed by Western immunoblotting with specific antibodies. (D–F) – Quantitative
analysis of Western immunoblotting of LC3 (D), Beclin-1 (E) and BAG-1 (F); the results are represented as fold change in comparison to control heart
samples. Quantitation of LC3 is calculated by analysing the expression ratio of LC3-II / LC3-I. The expression of Beclin-1 and BAG-1 is normalized with
the expression of GAPDH. *P 
 0.05 versus control. Results are representative images of three to five separate samples. C – Control, I/R – Ischaemia
and reperfusion, IA – Ischaemic adaptation followed by I/R, Wort  IA, Wortmannin treatment followed by IA.
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and it is suppressed by the treatment with PI3 kinase inhibitor
Wortmannin [33, 36]. In the present study, we treated rats with
Wortmannin in order to suppress the autophagy found during
ischaemic adaptation. Our results show that treatment of rats with
Wortmannin attenuated both LC3-II as well as BAG-1 protein
expression induced after cardiac adaptation against ischaemic
stress. Wortmannin treatment further attenuated the cardiac 
adaptation-induced improvement in cardiac functional parameters
(Fig. 4) and in myocardial infarct size (Fig. 5). Our results are in
accordance with other studies [43, 44], where Wortmannin has
been shown to abrogate the protective effects in the myocardium.
Though Wortmannin has been used as an inhibitor of autophagy
in several studies [33, 36], one cannot rule out the possibilities of
other effects of Wortmannin in the myocardium.
Role of BAG-1 in the induction of autophagy
In order to demonstrate the role of BAG-1 in the regulation of
autophagy, we adopted RNA interference technique to suppress
the expression of BAG-1 in vivo and in vitro by treating with 
BAG-1 siRNA. In vivo myocardial siRNA treatment was performed
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Fig. 6 In vivo treatment with BAG-1 siRNA attenuates the effects of ischaemic adaptation. BAG-1 and control siRNA was directly injected into the
myocardium of rats as mentioned in methods. 48 hrs after intramyocardial injection, hearts were isolated and subjected for ischaemic adaptation 
followed by I/R (IA) as mentioned in methods. Cardiac functional parameters like aortic flow (A), left ventricular developed pressure (B), and the first
derivative of left ventricular developed pressure (C, dp/dt) were measured in working mode during reperfusion at different time periods like 30, 60 and
120 min. B, Baseline. (D–F) – Quantitative analysis of Western blotting expression of BAG-1 (D), LC3 (E) and activated caspase-3 (F). The representa-
tive Western blot images are shown at the bottom. The results are represented as fold change in comparison to control siRNA treated heart samples.
Quantitation of LC3 is calculated by analysing the expression ratio of LC3-II / LC3-I. The expression of BAG-1 and activated caspase-3 is normalized
with the expression of GAPDH. (C) – Lactate dehydrogenase activity assay was performed with the coronary effluent collected at 2 hrs reperfusion
period. *P 
 0.05 versus control-siRNA of the same time period. Figures are representative images of three different samples.
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by direct injection of either BAG-1 or control siRNA into the rat
myocardium. Two days after siRNA treatment, the hearts were iso-
lated and subjected to ischaemic adaptation followed by I/R injury.
BAG-1 siRNA treatment attenuated cardiac adaptation-induced
improvement in cardiac functional parameters like left ventricular
developed pressure and aortic flow, and markedly reduced the
protein expression of BAG-1 and LC3-II relative to control siRNA
treated hearts (Fig. 6). Furthermore, BAG-1 siRNA treatment
enhanced myocardial damage demonstrated by elevated LDH
activity observed in the coronary effluent collected form BAG-1
siRNA treated hearts with respect to control siRNA treated hearts
(Fig. 6). Moreover, BAG-1 siRNA treatment in cardiac myoblast
cells resulted in attenuation of hypoxic adaptation-induced (i ) pro-
tein expression of BAG-1 and LC3-II, (ii ) reduction of LDH release
© 2009 The Authors
Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 7 Hypoxic adaptation in H9c2 cardiac myoblast cells induces autophagy. H9c2 cardiac myoblast cells were subjected to hypoxia followed by reoxy-
genation (H/R) or hypoxic adaptation (HA) as mentioned in methods section. (A)-Representative Western blot images showing the expression of LC3-I,
LC3-II and BAG-1 in total cell lysate. (B–C) – Quantitative analysis of Western immunoblotting of LC3 (B), and BAG-1 (C); the results are represented
as fold change in comparison to control cells. Quantitation of LC3 is calculated by analysing the expression ratio of LC3-II/LC3-I. The expression of
BAG-1 is normalized with the expression of GAPDH. *P 
 0.05 versus control. Results are representative images of three to five separate samples. 
N-normal, H/R-hypoxia and reperfusion, HA- hypoxic adaptation followed by H/R. (D–E) – Confocal microscopic images showing the expression of 
BAG-1 (D) and LC3 (E) in HA samples. (F) – Confocal microscopic images showing the colocalization of BAG-1 and LC3 in HA samples. Colocalization
is indicated by arrows. Counterstaining of nucleus in images D-F was done with Topro-1-iodide (Invitrogen). Figures are representative images of three
different samples.
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from cells and (iii ) improvement in cell survival (Fig. 8). These
results clearly indicate that treatment with BAG-1 siRNA in both
in vivo and in vitro attenuated ischaemic/hypoxic adaptation-
induced improvement in cardiac cell survival and autophagy.
However, further studies with overexpression of BAG-1 in the
myocardium may support the direct role of BAG-1 in the induc-
tion of autophagy. Though the cardioprotective role of multifunc-
tional protein BAG-1 has been ascertained in the recent years
[20–23], the present study indicates yet another role for BAG-1
conjugated with autophagy for the protection of myocardium
against I/R injury.
In summary, cardioprotective adaptive response to I/R or
hypoxia reoxygenation injury enhanced autophagic marker pro-
teins and BAG-1. The binding between BAG-1 and LC3 have been
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Fig. 8 In vitro BAG-1 siRNA treatment in H9c2 cells attenuate the effects of hypoxic adaptation H9c2 cardiac myoblast cells were subjected to 30 min.
of hypoxia and 60 min. reoxygenation (H/R). Hypoxic adaptation (HA) was given by subjecting the cells for three cyclic episodes of 5 min. of hypoxia
and 5 min. of reoxygenation, followed by H/R. A group of cells were treated with either control or BAG-1 siRNA as mentioned in methods. (A)-
Representative Western blot images showing the expression of BAG-1, LC3-I, LC3-II, and cleaved caspase-3 in total cell lysate. (B–D) – Quantitative
analysis of Western blotting expression of BAG-1 (B), LC3 (C) and activated caspase-3 (D). The results are represented as fold change in comparison
to normal cells. Quantitation of LC3 is calculated by analysing the expression ratio of LC3-II/LC3-I. The expression of BAG-1 and activated caspase-3 is
normalized with the expression of GAPDH. *P 
 0.05 versus N, #P 
 0.05 versus HA. (E) – Lactate dehydrogenase activity was measured using 
the spent culture medium collected at the end of the experiment. (C) – MTT assay was performed with the cultured cells as mentioned in methods. 
N, Normal cells; C-si, cells treated with control siRNA followed by HA; B-si, cells treated with BAG-1 siRNA followed by HA. * in (E) and (F) indicates
P 
 0.05 versus HA-control.
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demonstrated. Autophagic inhibition attenuated BAG-1 and car-
dioprotective adaptive responses. Suppression of BAG-1 with
BAG-1 siRNA treatment attenuated adaptation-induced autophagic
marker proteins cardiac improvements. These results indicate that
cardioprotective abilities of ischaemic adaptation are mediated at
least in part via up-regulation of autophagy, in association with
BAG-1 protein in the myocardium.
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